Modus Therapeutics Holding AB
Clinical-stage biotech developing a polysaccharide for systemic inflammation.
MODTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0015987904
- LEI:
- 984500C147FB4EF4A471
- Country:
- Sweden
- Address:
- Olof Palmes gata 29 IV, 111 22 STOCKHOLM
- Website:
- https://modustx.com/
Description
Modus Therapeutics Holding AB is a clinical-stage biotechnology company focused on developing its proprietary polysaccharide, sevuparin. The drug candidate is being developed as a potential treatment for diseases with significant unmet medical needs, particularly those involving systemic inflammation. The company's primary focus is on the development of sevuparin for sepsis and septic shock. Additional indications under investigation include anemia related to chronic inflammation, such as in patients with chronic kidney disease, and other disorders characterized by severe inflammation and impaired blood flow.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Modus Therapeutics Holding AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Modus Therapeutics Holding AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Modus Therapeutics Holding AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
